268 related articles for article (PubMed ID: 31691368)
21. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease.
Kuwana M; Shirai Y; Takeuchi T
J Rheumatol; 2016 Oct; 43(10):1825-1831. PubMed ID: 27481907
[TBL] [Abstract][Full Text] [Related]
22. Prognostic role of KL-6 in SSc-ILD patients with pleuroparenchymal fibroelastosis.
d'Alessandro M; Bellisai F; Bergantini L; Cameli P; D'Alessandro R; Mazzei MA; Gentili F; Conticini E; Selvi E; Frediani B; Matucci-Cerinic M; Bargagli E
Eur J Clin Invest; 2021 Aug; 51(8):e13543. PubMed ID: 33759179
[TBL] [Abstract][Full Text] [Related]
23. Usefulness and performance evaluation of serum KL-6 and SP-A assays in healthy individuals and patients with interstitial lung disease.
Cho EJ; Hong J; Hyun J; Lee W; Kim HS; Chun S; Min WK
Clin Biochem; 2023 Aug; 118():110609. PubMed ID: 37414329
[TBL] [Abstract][Full Text] [Related]
24. Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases.
Lederer C; Mayer K; Somogyi V; Kriegsmann K; Kriegsmann M; Buschulte K; Polke M; Findeisen P; Herth F; Kreuter M
Respiration; 2023; 102(8):591-600. PubMed ID: 37586349
[TBL] [Abstract][Full Text] [Related]
25. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
[TBL] [Abstract][Full Text] [Related]
26. Forensic application of three interstitial pneumonia markers: search for new pneumonia markers in dead bodies.
Okaba K; Inokuchi G; Horioka K; Iwase H; Inoue H; Motomura A; Ishii N; Moue C; Shiomi T; Yajima D
Int J Legal Med; 2024 Jul; 138(4):1583-1592. PubMed ID: 38379061
[TBL] [Abstract][Full Text] [Related]
27. Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease.
Watanabe S; Kase K; Saeki K; Ohkura N; Murata A; Waseda Y; Takato H; Ichikawa Y; Yasui M; Kasahara K
Respir Med; 2022 Jan; 191():106689. PubMed ID: 34844174
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease: A PRISMA-compliant systematic review and meta-analysis.
Zhang H; Chen L; Wu L; Huang J; Li H; Wang X; Weng H
Medicine (Baltimore); 2020 Apr; 99(16):e19493. PubMed ID: 32311922
[TBL] [Abstract][Full Text] [Related]
29. Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis.
Hu C; Wu C; Yang E; Huang H; Xu D; Hou Y; Zhao J; Li M; Xu Z; Zeng X; Wang Q
Clin Rheumatol; 2019 Aug; 38(8):2181-2187. PubMed ID: 30888566
[TBL] [Abstract][Full Text] [Related]
30. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review.
d'Alessandro M; Bergantini L; Cameli P; Vietri L; Lanzarone N; Alonzi V; Pieroni M; M Refini R; Sestini P; Bonella F; Bargagli E
Biomark Med; 2020 Jun; 14(8):665-674. PubMed ID: 32613855
[No Abstract] [Full Text] [Related]
31. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
[TBL] [Abstract][Full Text] [Related]
32. Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features.
Wang J; Zheng P; Huang Z; Huang H; Xue M; Liao C; Sun B; Zhong N
BMC Pulm Med; 2020 Dec; 20(1):315. PubMed ID: 33267857
[TBL] [Abstract][Full Text] [Related]
33. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases.
Ishikawa N; Hattori N; Yokoyama A; Kohno N
Respir Investig; 2012 Mar; 50(1):3-13. PubMed ID: 22554854
[TBL] [Abstract][Full Text] [Related]
34. Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II.
d'Alessandro M; Bergantini L; Cavallaro D; Gangi S; Cameli P; Conticini E; Siena Covid Unit ; Frediani B; Dotta F; Bargagli E
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206372
[TBL] [Abstract][Full Text] [Related]
35. Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C.
Ishikawa T; Kubota T; Abe H; Hirose K; Nagashima A; Togashi T; Seki K; Honma T; Yoshida T; Kamimura T
Hepatogastroenterology; 2012 Oct; 59(119):2260-3. PubMed ID: 23435141
[TBL] [Abstract][Full Text] [Related]
36. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
[TBL] [Abstract][Full Text] [Related]
37. KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
Zhang T; Shen P; Duan C; Gao L
Front Immunol; 2021; 12():745233. PubMed ID: 34956179
[TBL] [Abstract][Full Text] [Related]
38. Serum KL-6 levels in lung cancer patients with or without interstitial lung disease.
Miyazaki K; Kurishima K; Kagohashi K; Kawaguchi M; Ishikawa H; Satoh H; Hizawa N
J Clin Lab Anal; 2010; 24(5):295-9. PubMed ID: 20872562
[TBL] [Abstract][Full Text] [Related]
39. Potential of Krebs von den Lungen-6 as a predictor of relapse in interstitial pneumonia with anti-aminoacyl tRNA synthetase antibodies-positive dermatomyositis.
Isoda K; Kotani T; Takeuchi T; Konma J; Ishida T; Hata K; Otani K; Fujiwara H; Shoda T; Makino S; Arawaka S
Clin Respir J; 2018 Jul; 12(7):2235-2241. PubMed ID: 29633527
[TBL] [Abstract][Full Text] [Related]
40. Serum KL-6, CA19-9, CA125 and CEA are Diagnostic Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Chinese Population.
Zheng M; Lou A; Zhang H; Zhu S; Yang M; Lai W
Rheumatol Ther; 2021 Mar; 8(1):517-527. PubMed ID: 33586127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
